The statement comes as a study released by Oxfam, an global confederation of non-government organisations, showed a group of wealthy countries representing just 13 per cent of the world population have bought up over half the promised Covid-19 vaccine stocks.
There are nearly two dozen other countries negotiating with Russian Federation for the Sputnik V, which is named after the Soviet Union satellite used to compete with the United States during the Cold War space race.
In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers.
World Health Organization previously said 92 lower-income nations were seeking assistance via the scheme, and some 80 higherincome nations had expressed interest, but some still had to confirm their intention by the deadline. Global coronavirus cases exceeded 30 million on Thursday (17 September), according to a Reuters tally, and the pandemic shows no signs of slowing.
The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, developed by the University of Oxford.
Sanofi and GSK will also endeavour to provide a significant portion of their vaccine supply through a collaboration with the COVID-19 Vaccines Global Access (COVAX) facility - the vaccine pillar of the Access to COVID-19 Tools Accelerator for lower and middle income countries - in a timely manner.
The vast majority of them are in good health, the anti-coronavirus crisis centre had told reporters.
Most vaccines in development will require two doses per person.
The CDC anticipates that 35 million to 45 million doses of vaccines from the first two companies to receive authorization will be available in the United States by the end of this year.
The Philippines' purchase and distribution of Covid-19 vaccines can only be made starting the second quarter of 2021 as delays hit the review of possible candidates, an official said.
"We support the Facility's goal to deliver two billion doses of safe and effective Covid-19 vaccines by 2021, and welcome that it now manages the world's largest and most diverse Covid-19 vaccine portfolio".
However, the European Union has publicly said it wants to boost the production capacity of vaccine makers and share any excess doses with poorer nations.
It is unclear when a vaccine will be available for children as major drugmakers have yet to include them in late-stage trials.